RGNX

Regenxbio Inc. is a leading clinical-stage biotechnology company based in Rockville, Maryland, focused on pioneering gene therapies for genetic disorders. Utilizing its proprietary AAV9 gene delivery platform, the company is developing innovative treatments that enable cells to produce vital therapeutic proteins and antibodies to modulate diseases. With a robust pipeline aimed at addressing serious genetic conditions, Regenxbio is committed to transforming patient outcomes and addressing significant unmet medical needs within the therapeutic landscape. Through its cutting-edge research and development efforts, Regenxbio is positioned to be a key player in the evolving field of gene therapy.